论文部分内容阅读
本文对31例不稳定性心绞痛病人给予尿激酶并肝素治疗,并用29例肝素治疗不稳定性心绞痛病人相对照,结果显示尿激酶并肝素组有效率93.55％,明显优于肝素组68.97％(P<0.05),尿激酶并肝素组心绞痛缓解,消失时间明显较肝素组缩短20小时(P<0.01),而心电图、血液流变学的改善尿激酶并肝素组均明显优于肝素组(P<0.05或P<0.01),且无明显副作用。我们认为尿激酶并肝素溶栓抗凝作用相互协同,治疗不稳定性心绞痛疗效显著,安全可行,值得推广。
In this paper, 31 patients with unstable angina were treated with urokinase and heparin, and 29 patients with unstable angina were treated with heparin. The results showed that the effective rate of urokinase and heparin was 93.55%, which was significantly higher than that of heparin (68.97%, P (P <0.01). However, ECG and hemorrheological improvement in urokinase and heparin group were significantly better than those in heparin group (P < 0.05 or P <0.01), and no obvious side effects. We believe that urokinase and heparin thrombolysis anticoagulant synergistic effect of treatment of unstable angina significant effect, safe and feasible, it is worth promoting.